JP2016534059A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016534059A5 JP2016534059A5 JP2016525063A JP2016525063A JP2016534059A5 JP 2016534059 A5 JP2016534059 A5 JP 2016534059A5 JP 2016525063 A JP2016525063 A JP 2016525063A JP 2016525063 A JP2016525063 A JP 2016525063A JP 2016534059 A5 JP2016534059 A5 JP 2016534059A5
- Authority
- JP
- Japan
- Prior art keywords
- acceptable salt
- compound
- pharmaceutical composition
- effective amount
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KFLQYBLSEZRKTN-MOPGFXCFSA-N CC(N(CC[C@H]1NC(C=C)=O)C[C@@H]1Nc1nc(ccc(-c(c(Cl)c(cc2OC)OC)c2Cl)c2)c2cn1)=O Chemical compound CC(N(CC[C@H]1NC(C=C)=O)C[C@@H]1Nc1nc(ccc(-c(c(Cl)c(cc2OC)OC)c2Cl)c2)c2cn1)=O KFLQYBLSEZRKTN-MOPGFXCFSA-N 0.000 description 1
- 0 CCN(C1O)c2cc(N[C@](CCCC3)[C@]3NC(C#C)=O)ncc2C=C1c(c(Cl)c(*)cc1OC)c1Cl Chemical compound CCN(C1O)c2cc(N[C@](CCCC3)[C@]3NC(C#C)=O)ncc2C=C1c(c(Cl)c(*)cc1OC)c1Cl 0.000 description 1
- ZAOOOJFIXJSQSK-QWHCGFSZSA-N CCN(c(nc(N[C@H](CCC1)[C@H]1NC(C=C)=O)nc1)c1N=C1c(c(Cl)c(cc2OC)OC)c2Cl)C1=O Chemical compound CCN(c(nc(N[C@H](CCC1)[C@H]1NC(C=C)=O)nc1)c1N=C1c(c(Cl)c(cc2OC)OC)c2Cl)C1=O ZAOOOJFIXJSQSK-QWHCGFSZSA-N 0.000 description 1
- NGHDVDVDUXSERF-LTWKBGODSA-N CCN(c1c(C=C2c(c(Cl)c(cc3OC)OC)c3Cl)cnc(N[C@H](CCC3)[C@H]3N(C[C@@H](C[C@@H]3NC(C=C)=O)OC[C@H]3Nc3nc(ccc(-c(c(Cl)c(cc4OC)OC)c4Cl)c4)c4cn3)C(C=C)=O)n1)C2=O Chemical compound CCN(c1c(C=C2c(c(Cl)c(cc3OC)OC)c3Cl)cnc(N[C@H](CCC3)[C@H]3N(C[C@@H](C[C@@H]3NC(C=C)=O)OC[C@H]3Nc3nc(ccc(-c(c(Cl)c(cc4OC)OC)c4Cl)c4)c4cn3)C(C=C)=O)n1)C2=O NGHDVDVDUXSERF-LTWKBGODSA-N 0.000 description 1
- ILXYIVJPIDOKJQ-JKSUJKDBSA-N CN(c1cc(N[C@H](COCC2)[C@H]2NC(C=C)=O)ncc1C=C1c(c(Cl)c(cc2OC)OC)c2Cl)C1=O Chemical compound CN(c1cc(N[C@H](COCC2)[C@H]2NC(C=C)=O)ncc1C=C1c(c(Cl)c(cc2OC)OC)c2Cl)C1=O ILXYIVJPIDOKJQ-JKSUJKDBSA-N 0.000 description 1
- JHMGYDVAEUYQHL-UHFFFAOYSA-N COc(cc(c(Cl)c1-c(cc2)cc3c2nc(NC2CCCCC2)nc3)OC)c1Cl Chemical compound COc(cc(c(Cl)c1-c(cc2)cc3c2nc(NC2CCCCC2)nc3)OC)c1Cl JHMGYDVAEUYQHL-UHFFFAOYSA-N 0.000 description 1
- WEYGASMDUSXWOC-MSOLQXFVSA-N COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@@H](CCCC2)[C@@H]2NC(C=C)=O)nc3)OC)c1Cl Chemical compound COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@@H](CCCC2)[C@@H]2NC(C=C)=O)nc3)OC)c1Cl WEYGASMDUSXWOC-MSOLQXFVSA-N 0.000 description 1
- NCKDVUYBTAQHDX-COYJEINXSA-N COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@@H](CCCC2)[C@H]2NC(/C=C\COc(c(Cl)c2-c4ccc5nc(N[C@@H](CNCC6)[C@@H]6NC(C=C)=O)ncc5c4)cc(OC)c2Cl)=O)nc3)OC)c1Cl Chemical compound COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@@H](CCCC2)[C@H]2NC(/C=C\COc(c(Cl)c2-c4ccc5nc(N[C@@H](CNCC6)[C@@H]6NC(C=C)=O)ncc5c4)cc(OC)c2Cl)=O)nc3)OC)c1Cl NCKDVUYBTAQHDX-COYJEINXSA-N 0.000 description 1
- BVDNESAVRVJTNC-CCLHPLFOSA-N COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@@H]([C@H](C2)NC(C#C)=O)c4c2cccc4)nc3)OC)c1Cl Chemical compound COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@@H]([C@H](C2)NC(C#C)=O)c4c2cccc4)nc3)OC)c1Cl BVDNESAVRVJTNC-CCLHPLFOSA-N 0.000 description 1
- WEYGASMDUSXWOC-QZTJIDSGSA-N COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@H](CCCC2)[C@@H]2NC(C=C)=O)nc3)OC)c1Cl Chemical compound COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@H](CCCC2)[C@@H]2NC(C=C)=O)nc3)OC)c1Cl WEYGASMDUSXWOC-QZTJIDSGSA-N 0.000 description 1
- WEYGASMDUSXWOC-ZWKOTPCHSA-N COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@H](CCCC2)[C@H]2NC(C=C)=O)nc3)OC)c1Cl Chemical compound COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@H](CCCC2)[C@H]2NC(C=C)=O)nc3)OC)c1Cl WEYGASMDUSXWOC-ZWKOTPCHSA-N 0.000 description 1
- GKQWMHRQOVMSIE-SJORKVTESA-N COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@H](CCOC2)[C@H]2NC(C=C)=O)nc3)OC)c1Cl Chemical compound COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@H](CCOC2)[C@H]2NC(C=C)=O)nc3)OC)c1Cl GKQWMHRQOVMSIE-SJORKVTESA-N 0.000 description 1
- JPCIRONPDKKKBK-DLBZAZTESA-N COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@H](CNCC2)[C@H]2NC(C=C)=O)nc3)OC)c1Cl Chemical compound COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@H](CNCC2)[C@H]2NC(C=C)=O)nc3)OC)c1Cl JPCIRONPDKKKBK-DLBZAZTESA-N 0.000 description 1
- MGZKYOAQVGSSGC-DLBZAZTESA-N COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@H](COCC2)[C@H]2NC(C=C)=O)nc3)OC)c1Cl Chemical compound COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@H](COCC2)[C@H]2NC(C=C)=O)nc3)OC)c1Cl MGZKYOAQVGSSGC-DLBZAZTESA-N 0.000 description 1
- FRVZTFULMVCLRE-HYVNUMGLSA-N COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@H](C[C@@H](C2)O)[C@H]2NC(C=C)=O)nc3)OC)c1Cl Chemical compound COc(cc(c(Cl)c1-c(cc2)cc3c2nc(N[C@H](C[C@@H](C2)O)[C@H]2NC(C=C)=O)nc3)OC)c1Cl FRVZTFULMVCLRE-HYVNUMGLSA-N 0.000 description 1
- AWQOOPSJCUIVQO-JKSUJKDBSA-N COc(cc(c(Cl)c1-c(cc2Cl)cc3c2nc(N[C@H](COCC2)[C@H]2NC(C=C)=O)nc3)OC)c1Cl Chemical compound COc(cc(c(Cl)c1-c(cc2Cl)cc3c2nc(N[C@H](COCC2)[C@H]2NC(C=C)=O)nc3)OC)c1Cl AWQOOPSJCUIVQO-JKSUJKDBSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361895472P | 2013-10-25 | 2013-10-25 | |
| US61/895,472 | 2013-10-25 | ||
| US201461927782P | 2014-01-15 | 2014-01-15 | |
| US61/927,782 | 2014-01-15 | ||
| PCT/US2014/061974 WO2015061572A1 (en) | 2013-10-25 | 2014-10-23 | Inhibitors of the fibroblast growth factor receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018186710A Division JP2019019131A (ja) | 2013-10-25 | 2018-10-01 | 繊維芽細胞成長因子受容体の阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016534059A JP2016534059A (ja) | 2016-11-04 |
| JP2016534059A5 true JP2016534059A5 (cg-RX-API-DMAC7.html) | 2017-11-30 |
| JP6458023B2 JP6458023B2 (ja) | 2019-01-23 |
Family
ID=51947473
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525063A Active JP6458023B2 (ja) | 2013-10-25 | 2014-10-23 | 繊維芽細胞成長因子受容体の阻害剤 |
| JP2018186710A Pending JP2019019131A (ja) | 2013-10-25 | 2018-10-01 | 繊維芽細胞成長因子受容体の阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018186710A Pending JP2019019131A (ja) | 2013-10-25 | 2018-10-01 | 繊維芽細胞成長因子受容体の阻害剤 |
Country Status (27)
Families Citing this family (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| BR112014030812B1 (pt) | 2012-06-13 | 2022-11-08 | Incyte Holdings Corporation | Compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr |
| CN109627239B (zh) * | 2012-07-11 | 2021-10-12 | 缆图药品公司 | 成纤维细胞生长因子受体的抑制剂 |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| KR102350704B1 (ko) | 2013-03-15 | 2022-01-13 | 셀젠 카르 엘엘씨 | 헤테로아릴 화합물 및 이의 용도 |
| AR095464A1 (es) | 2013-03-15 | 2015-10-21 | Celgene Avilomics Res Inc | Compuestos de heteroarilo y usos de los mismos |
| EP2970231A1 (en) | 2013-03-15 | 2016-01-20 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| EA036160B1 (ru) | 2013-03-15 | 2020-10-08 | Селджен Кар Ллс | Гетероарильные соединения и их применение |
| ME03015B (me) | 2013-04-19 | 2018-10-20 | Incyte Holdings Corp | Biciklični heterocikli kao fgfr inhibitori |
| HUE039687T2 (hu) | 2013-10-17 | 2019-01-28 | Blueprint Medicines Corp | Kompozíciók, amelyek alkalmazhatók KIT-tel kapcsolatos rendellenességek kezelésében való alkalmazásra |
| PH12016500676B1 (en) | 2013-10-18 | 2022-07-20 | Eisai R&D Man Co Ltd | Pyrimidine fgfr4 inhibitors |
| PE20160546A1 (es) | 2013-10-25 | 2016-05-26 | Novartis Ag | Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4 |
| PH12016500739B1 (en) | 2013-10-25 | 2022-04-29 | Blueprint Medicines Corp | Inhibitors of the fibrolast growth factor receptor |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| US9828373B2 (en) | 2014-07-26 | 2017-11-28 | Sunshine Lake Pharma Co., Ltd. | 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof |
| PL3200786T3 (pl) | 2014-10-03 | 2020-03-31 | Novartis Ag | Zastosowanie pochodnych pirydylowych o skondensowanym układzie bicyklicznym jako inhibitorów fgfr4 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
| AU2016248056B2 (en) | 2015-04-14 | 2020-07-23 | Eisai R&D Management Co., Ltd. | Crystalline FGFR4 inhibitor compound and uses thereof |
| PT3322706T (pt) | 2015-07-16 | 2021-03-08 | Array Biopharma Inc | Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret |
| JP2018521076A (ja) | 2015-07-24 | 2018-08-02 | ブループリント メディシンズ コーポレイション | Ｋｉｔ及びｐｄｇｆｒに関連する疾病を治療するのに有用な化合物 |
| KR20180043810A (ko) | 2015-08-26 | 2018-04-30 | 블루프린트 메디신즈 코포레이션 | Ntrk에 관련된 장애 치료용으로 유용한 화합물 및 조성물 |
| SG11201803438XA (en) | 2015-10-26 | 2018-05-30 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| IL288519B2 (en) | 2015-11-02 | 2023-09-01 | Blueprint Medicines Corp | inhibitors of ret |
| SG10201912607SA (en) | 2015-11-19 | 2020-02-27 | Blueprint Medicines Corp | Compounds and compositions useful for treating disorders related to ntrk |
| US10183928B2 (en) | 2016-03-17 | 2019-01-22 | Blueprint Medicines Corporation | Inhibitors of RET |
| JP7057343B2 (ja) | 2016-04-04 | 2022-04-19 | ロクソ オンコロジー， インコーポレイテッド | 小児癌の処置方法 |
| PE20181888A1 (es) | 2016-04-04 | 2018-12-11 | Loxo Oncology Inc | Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| US10233186B2 (en) | 2016-04-15 | 2019-03-19 | Blueprint Medicines Corporation | Inhibitors of activin receptor-like kinase |
| US11357769B2 (en) | 2016-05-10 | 2022-06-14 | Eisai R&D Management Co., Ltd. | Drug combinations for reducing cell viability and/or cell proliferation |
| HUE053643T2 (hu) | 2016-05-18 | 2021-07-28 | Loxo Oncology Inc | (S)-N-(5 -((R)-2-(2,5-difluor-fenil)-pirrolidin-1-il)-pirazolo[1,5-A] pirimidin-3-il)-3-hidroxi-pirrolidin-1-karboxamid elõkészítése |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| WO2018022761A1 (en) | 2016-07-27 | 2018-02-01 | Blueprint Medicines Corporation | Substituted cyclopentane-amides for treating disorders related to ret |
| JP6751977B2 (ja) * | 2016-09-01 | 2020-09-09 | 南京薬捷安康生物科技有限公司 | 線維芽細胞増殖因子受容体の阻害剤及びそれらの使用 |
| CN110022900A (zh) * | 2016-09-08 | 2019-07-16 | 蓝图药品公司 | 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合 |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| CN106986809B (zh) * | 2016-12-02 | 2020-03-24 | 广东省微生物研究所（广东省微生物分析检测中心） | 一种5-溴-6-氯-3-吲哚辛酯的合成方法 |
| EP3524603B1 (en) * | 2016-12-19 | 2022-06-08 | Abbisko Therapeutics Co., Ltd. | Fgfr4 inhibitor, preparation method therefor and pharmaceutical use thereof |
| CN108264511B (zh) * | 2017-01-03 | 2021-04-13 | 浙江海正药业股份有限公司 | 杂环类衍生物及其制备方法和其在医药上的用途 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| WO2018136661A1 (en) | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
| CN108503593B (zh) * | 2017-02-28 | 2021-04-27 | 暨南大学 | 2-氨基嘧啶类化合物及其应用 |
| US11192890B2 (en) * | 2017-03-03 | 2021-12-07 | Auckland Uniservices Limited | FGFR kinase inhibitors and pharmaceutical uses |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| US11040979B2 (en) | 2017-03-31 | 2021-06-22 | Blueprint Medicines Corporation | Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR |
| CN108689878B (zh) * | 2017-04-10 | 2023-05-09 | 浙江九洲药业股份有限公司 | 光学活性二氨基衍生物的制备方法 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| EP3680236A4 (en) * | 2017-09-05 | 2021-04-21 | Bioardis LLC | AROMATIC DERIVATIVE, MANUFACTURING PROCESS FOR IT AND MEDICAL APPLICATION OF IT |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| CN111566102B (zh) | 2017-10-18 | 2023-09-08 | 缆图药品公司 | 作为激活素受体样激酶抑制剂的取代的吡咯并吡啶 |
| IL274274B2 (en) * | 2017-11-01 | 2023-11-01 | Guangdong Zhongsheng Pharmaceutical Co Ltd | Salt form and crystal form of compound as fgfr4 inhibitor and preparation method thereof |
| CN109745325B (zh) * | 2017-11-08 | 2022-02-15 | 上海翰森生物医药科技有限公司 | Fgfr4抑制剂、其制备方法和用途 |
| CN111630054B (zh) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物 |
| WO2019143994A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| TWI802635B (zh) | 2018-01-18 | 2023-05-21 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物 |
| HRP20240124T1 (hr) | 2018-04-03 | 2024-04-12 | Blueprint Medicines Corporation | Inhibitori za ret za uporabu u liječenju raka koji ima ret alteraciju |
| SG11202010636VA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Solid forms of an fgfr inhibitor and processes for preparing the same |
| TW201946630A (zh) | 2018-05-04 | 2019-12-16 | 美商英塞特公司 | Fgfr抑制劑之鹽 |
| CN111868058B (zh) * | 2018-05-25 | 2023-06-13 | 上海和誉生物医药科技有限公司 | 一种fgfr抑制剂、其制备方法和在药学上的应用 |
| CA3224985C (en) | 2018-07-31 | 2025-11-18 | Loxo Oncology, Inc. | SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE |
| WO2020055672A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| EA202190885A1 (ru) | 2018-09-27 | 2021-06-25 | Бетта Фармасьютикалз Ко., Лтд | Ингибитор fgfr4 и его применение |
| CN110950867A (zh) * | 2018-09-27 | 2020-04-03 | 首药控股(北京)有限公司 | 一种fgfr4激酶抑制剂及其制备方法和用途 |
| CN111138459B (zh) * | 2018-11-06 | 2022-10-18 | 南京圣和药业股份有限公司 | Fgfr4抑制剂的光学异构体及其应用 |
| WO2020119606A1 (en) * | 2018-12-10 | 2020-06-18 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as inhibitors of fibroblast growth factor receptor |
| US12180207B2 (en) | 2018-12-19 | 2024-12-31 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases |
| EP3898615A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
| WO2020177067A1 (en) | 2019-03-05 | 2020-09-10 | Bioardis Llc | Aromatic derivatives, preparation methods, and medical uses thereof |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| RS64881B1 (sr) | 2019-04-12 | 2023-12-29 | Blueprint Medicines Corp | Kristalini oblici (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f][1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amin i načini pripreme |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021023193A1 (zh) * | 2019-08-08 | 2021-02-11 | 漳州片仔癀药业股份有限公司 | 吡嗪-2(1h)-酮类化合物的制备方法 |
| EP4011866B1 (en) * | 2019-08-08 | 2023-07-26 | Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. | Crystalline form a and crystalline form b of pyrazine-2(1h)-ketone compound and preparation method thereof |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN112759593A (zh) | 2019-11-01 | 2021-05-07 | 北京伯汇生物技术有限公司 | 桥环并醛基吡啶衍生物及其应用 |
| CN114728058A (zh) * | 2019-11-04 | 2022-07-08 | 基石药业（苏州）有限公司 | Fgfr4/pd-1组合治疗 |
| AU2020395185A1 (en) | 2019-12-04 | 2022-06-02 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| EP4069369A4 (en) | 2019-12-06 | 2024-02-14 | Schrödinger, Inc. | CYCLIC COMPOUNDS AND METHODS OF USE THEREOF |
| CN113087696A (zh) * | 2019-12-23 | 2021-07-09 | 江苏开元药业有限公司 | 喹啉类化合物及其应用 |
| PH12022551523A1 (en) | 2019-12-27 | 2024-01-29 | SchraDinger Inc | Cyclic compounds and methods of using same |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP2023519011A (ja) | 2020-03-27 | 2023-05-09 | ▲貝▼▲達▼▲薬▼▲業▼股▲フン▼有限公司 | Ｆｇｆｒ４阻害剤の塩形、結晶形及びその使用 |
| US12448366B2 (en) | 2020-05-29 | 2025-10-21 | Rigel Pharmaceuticals, Inc. | Solid forms of pralsetinib |
| JP2023541047A (ja) | 2020-09-10 | 2023-09-27 | シュレーディンガー， インコーポレイテッド | がんの治療のための複素環式ペリ縮環ｃｄｃ７キナーゼ阻害剤 |
| EP4215534A4 (en) | 2020-09-18 | 2024-10-02 | Carna Biosciences, Inc. | AMINE DERIVATIVE |
| US12205625B2 (en) * | 2020-09-18 | 2025-01-21 | Semiconductor Energy Laboratory Co., Ltd. | Semiconductor device and electronic device |
| IL301883A (en) | 2020-10-05 | 2023-06-01 | Chiome Bioscience Inc | Medicament for treating cancer |
| EP4284804A1 (en) | 2021-01-26 | 2023-12-06 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders |
| WO2022194160A1 (zh) * | 2021-03-16 | 2022-09-22 | 上海启晟合研医药科技有限公司 | 非索替尼固体形式及其制备方法 |
| TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
| BR112023019135A2 (pt) * | 2021-03-26 | 2023-10-24 | Apeloa Pharmaceutical Co Ltd | Compostos, composição farmacêutica, preparação farmacêutica e uso, método e forma de combinação farmacêutica destes |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| TWI896159B (zh) * | 2023-06-09 | 2025-09-01 | 大陸商上海和譽生物醫藥科技有限公司 | 一種fgfr4抑制劑組合物、其製備方法和在藥學上的應用 |
| WO2025059027A1 (en) | 2023-09-11 | 2025-03-20 | Schrödinger, Inc. | Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors |
| CN118221569A (zh) * | 2024-03-22 | 2024-06-21 | 浙江大学 | 一种环戊烷-1,2-二胺衍生物及其制备方法 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ296456A (en) | 1994-11-14 | 1999-09-29 | Warner Lambert Co | 6-aryl pyrido[2,3-d]pyrimidines and naphthyridines; inhibition of protein tyrosine kinase mediated cellular proliferation |
| IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| GB9708917D0 (en) | 1997-05-01 | 1997-06-25 | Pfizer Ltd | Compounds useful in therapy |
| TR200003429T2 (tr) | 1998-05-26 | 2001-07-23 | Warner-Lambert Company | Hücresel çoğalma inhibitörleri olarak bisiklik pirimidinler ve bisiklik 3,4-dihidropirimidinler. |
| US6403799B1 (en) | 1999-10-21 | 2002-06-11 | Agouron Pharmaceuticals, Inc. | Methods for the preparation of intermediates in the synthesis of HIV-protease inhibitors |
| TR200201057T2 (tr) | 1999-10-21 | 2002-09-23 | F.Hoffmann-La Roche Ag | P38 protein kinazı inhibitörleri olarak heteroalkilamino ikameli bisiklik nitrojen heterosaykılları. |
| CA2386955A1 (en) | 1999-11-22 | 2001-05-31 | Warner-Lambert Company | Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
| US6605615B2 (en) | 2000-03-01 | 2003-08-12 | Tularik Inc. | Hydrazones and analogs as cholesterol lowering agents |
| ATE408613T1 (de) | 2000-08-04 | 2008-10-15 | Warner Lambert Co | 2-(4-pyridyl)amino-6-dialkoxyphenyl-pyrido(2,3- d)pyrimidin-7-one |
| US6653313B2 (en) | 2000-08-10 | 2003-11-25 | Warner-Lambert Company Llc | 1,4-dihydropyridine compounds as bradykinin antagonists |
| WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| KR100669578B1 (ko) | 2002-01-22 | 2007-01-15 | 워너-램버트 캄파니 엘엘씨 | 2-(피리딘-2-일아미노)-피리도[2,3-ｄ]피리미딘-7-온 |
| US20050009849A1 (en) | 2003-01-03 | 2005-01-13 | Veach Darren R. | Pyridopyrimidine kinase inhibitors |
| WO2005030131A2 (en) | 2003-09-23 | 2005-04-07 | Replidyne, Inc | Bis-quinazoline compounds for the treatment of bacterial infections |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| CN101107248A (zh) | 2005-01-28 | 2008-01-16 | 埃科特莱茵药品有限公司 | 作为用于治疗高血压的肾素抑制剂的7－{4－[2－(2,6－二氯－4－甲基苯氧基)乙氧基]苯基}－3,9－二氮杂双环[3.3.1]壬－6－烯－6－羧酸环丙基－(2,3－二甲基苄基)酰胺 |
| EP1878727A4 (en) | 2005-04-28 | 2013-11-13 | Kyowa Hakko Kirin Co Ltd | 2-AMINOQUINAZOLINE DERIVATIVES |
| HRP20150642T1 (hr) | 2006-12-22 | 2015-08-14 | Astex Therapeutics Limited | BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a |
| CA2673003A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Quinazolines for pdk1 inhibition |
| US20110160232A1 (en) | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
| CA3031835C (en) | 2008-06-27 | 2021-09-07 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| JP2012501637A (ja) | 2008-09-03 | 2012-01-26 | ライセンティア・リミテッド | Ｆｇｆｒ４に関連する癌細胞浸潤を抑制するための材料および方法 |
| WO2010028236A1 (en) | 2008-09-05 | 2010-03-11 | Avila Therapeutics, Inc. | Algorithm for designing irreversible inhibitors |
| JP2012514020A (ja) | 2008-12-29 | 2012-06-21 | フォーヴィア・ファーマシューティカルズ | 置換キナゾリン化合物 |
| PE20120795A1 (es) | 2009-08-07 | 2012-07-08 | Chugai Pharmaceutical Co Ltd | Derivado de aminopirazol |
| CN102713618B (zh) | 2009-09-16 | 2015-07-15 | 新基阿维罗米克斯研究公司 | 蛋白激酶复合物和抑制剂 |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| KR102055331B1 (ko) | 2011-04-21 | 2019-12-12 | 아이오니스 파마수티컬즈, 인코포레이티드 | B형 간염 바이러스(hbv) 발현 조절 |
| MX355728B (es) | 2011-05-17 | 2018-04-27 | Univ California | Inhibidores de cinasas. |
| FR2985257B1 (fr) | 2011-12-28 | 2014-02-14 | Sanofi Sa | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
| CN103958512B (zh) | 2012-01-19 | 2016-01-20 | 大鹏药品工业株式会社 | 3,5-双取代炔基苯化合物及其盐 |
| WO2013118817A1 (ja) * | 2012-02-07 | 2013-08-15 | 大鵬薬品工業株式会社 | キノリルピロロピリミジン化合物又はその塩 |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| CN109627239B (zh) | 2012-07-11 | 2021-10-12 | 缆图药品公司 | 成纤维细胞生长因子受体的抑制剂 |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| WO2014044846A1 (en) | 2012-09-24 | 2014-03-27 | Evotec (Uk) Ltd. | 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia |
| TWI629266B (zh) | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | 纖維母細胞生長因子受體之抑制劑 |
| KR101858913B1 (ko) | 2013-02-21 | 2018-05-16 | 화이자 인코포레이티드 | 고체 형태의 선택적인 cdk4/6 억제제 |
| AR095464A1 (es) | 2013-03-15 | 2015-10-21 | Celgene Avilomics Res Inc | Compuestos de heteroarilo y usos de los mismos |
| EA036160B1 (ru) * | 2013-03-15 | 2020-10-08 | Селджен Кар Ллс | Гетероарильные соединения и их применение |
| EP2970231A1 (en) | 2013-03-15 | 2016-01-20 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| HUE039687T2 (hu) | 2013-10-17 | 2019-01-28 | Blueprint Medicines Corp | Kompozíciók, amelyek alkalmazhatók KIT-tel kapcsolatos rendellenességek kezelésében való alkalmazásra |
| PH12016500676B1 (en) | 2013-10-18 | 2022-07-20 | Eisai R&D Man Co Ltd | Pyrimidine fgfr4 inhibitors |
| PE20160546A1 (es) | 2013-10-25 | 2016-05-26 | Novartis Ag | Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4 |
| PH12016500739B1 (en) | 2013-10-25 | 2022-04-29 | Blueprint Medicines Corp | Inhibitors of the fibrolast growth factor receptor |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| US9715813B1 (en) | 2014-03-02 | 2017-07-25 | Durex International Corp | Visibility electronic controller and current-based status monitor |
| WO2016022569A1 (en) | 2014-08-04 | 2016-02-11 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| US20160115164A1 (en) | 2014-10-22 | 2016-04-28 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| JP2018521076A (ja) | 2015-07-24 | 2018-08-02 | ブループリント メディシンズ コーポレイション | Ｋｉｔ及びｐｄｇｆｒに関連する疾病を治療するのに有用な化合物 |
| KR20180043810A (ko) | 2015-08-26 | 2018-04-30 | 블루프린트 메디신즈 코포레이션 | Ntrk에 관련된 장애 치료용으로 유용한 화합물 및 조성물 |
| MX382526B (es) | 2015-10-23 | 2025-03-13 | Array Biopharma Inc | Compuestos de 2-piridazin-3(2h)-ona 2-aril sustituidas y 2-heteroaril sustituidas como inhibidores de las tirosina quinasas fgfr |
| IL288519B2 (en) | 2015-11-02 | 2023-09-01 | Blueprint Medicines Corp | inhibitors of ret |
| SG10201912607SA (en) | 2015-11-19 | 2020-02-27 | Blueprint Medicines Corp | Compounds and compositions useful for treating disorders related to ntrk |
| US10183928B2 (en) | 2016-03-17 | 2019-01-22 | Blueprint Medicines Corporation | Inhibitors of RET |
| US10233186B2 (en) | 2016-04-15 | 2019-03-19 | Blueprint Medicines Corporation | Inhibitors of activin receptor-like kinase |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| WO2018022761A1 (en) | 2016-07-27 | 2018-02-01 | Blueprint Medicines Corporation | Substituted cyclopentane-amides for treating disorders related to ret |
| CN110022900A (zh) | 2016-09-08 | 2019-07-16 | 蓝图药品公司 | 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合 |
-
2014
- 2014-10-23 PH PH1/2016/500739A patent/PH12016500739B1/en unknown
- 2014-10-23 CN CN201910274804.3A patent/CN110028491B/zh active Active
- 2014-10-23 KR KR1020167012396A patent/KR102405452B1/ko active Active
- 2014-10-23 WO PCT/US2014/061974 patent/WO2015061572A1/en not_active Ceased
- 2014-10-23 RU RU2016120012A patent/RU2704112C2/ru active
- 2014-10-23 EP EP14802532.3A patent/EP3060560A1/en not_active Withdrawn
- 2014-10-23 HR HRP20220840TT patent/HRP20220840T1/hr unknown
- 2014-10-23 CN CN201480058647.8A patent/CN105658642B/zh active Active
- 2014-10-23 CA CA2928042A patent/CA2928042C/en active Active
- 2014-10-23 DK DK18177131.2T patent/DK3395814T3/da active
- 2014-10-23 SI SI201431968T patent/SI3395814T1/sl unknown
- 2014-10-23 JP JP2016525063A patent/JP6458023B2/ja active Active
- 2014-10-23 BR BR112016008849A patent/BR112016008849B8/pt active IP Right Grant
- 2014-10-23 US US14/521,909 patent/US9434700B2/en active Active
- 2014-10-23 PL PL18177131.2T patent/PL3395814T3/pl unknown
- 2014-10-23 PT PT181771312T patent/PT3395814T/pt unknown
- 2014-10-23 MX MX2016005297A patent/MX2016005297A/es active IP Right Grant
- 2014-10-23 SM SM20220292T patent/SMT202200292T1/it unknown
- 2014-10-23 EP EP18177131.2A patent/EP3395814B1/en active Active
- 2014-10-23 HU HUE18177131A patent/HUE059037T2/hu unknown
- 2014-10-23 RS RS20220624A patent/RS63405B1/sr unknown
- 2014-10-23 AU AU2014339972A patent/AU2014339972B9/en active Active
- 2014-10-23 ES ES18177131T patent/ES2924111T3/es active Active
- 2014-10-23 LT LTEP18177131.2T patent/LT3395814T/lt unknown
- 2014-10-24 UY UY0001035798A patent/UY35798A/es unknown
- 2014-10-24 TW TW103136870A patent/TWI675828B/zh active
-
2016
- 2016-03-22 ZA ZA2016/01971A patent/ZA201601971B/en unknown
- 2016-03-23 IL IL244738A patent/IL244738B/en unknown
- 2016-07-28 US US15/222,523 patent/US10221154B2/en active Active
-
2018
- 2018-10-01 JP JP2018186710A patent/JP2019019131A/ja active Pending
-
2019
- 2019-02-19 US US16/279,904 patent/US10875837B2/en active Active
-
2020
- 2020-11-24 US US17/102,628 patent/US20210347756A1/en not_active Abandoned
-
2022
- 2022-07-05 CY CY20221100453T patent/CY1125393T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016534059A5 (cg-RX-API-DMAC7.html) | ||
| RU2016120012A (ru) | Ингибиторы рецептора фактора роста фибробластов | |
| EA201991399A1 (ru) | Аминотриазолопиридиновые соединения и их применение в лечении рака | |
| EP4321513A3 (en) | Pyrrolotriazine compounds as tam inhibitors | |
| JP2018511590A5 (cg-RX-API-DMAC7.html) | ||
| EP4253366A3 (en) | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection | |
| EA201790246A1 (ru) | Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы | |
| EA201991693A1 (ru) | Производное пиридина в качестве ингибитора ask1 и способ его получения и применения | |
| EA201001126A1 (ru) | Пирролопиримидины и пирролопиридины | |
| JP2015523383A5 (cg-RX-API-DMAC7.html) | ||
| JP2017536344A5 (cg-RX-API-DMAC7.html) | ||
| WO2015200481A8 (en) | Mnk inhibitors and methods related thereto | |
| EP3954679A3 (en) | Amide compounds for the treatment of hiv infections | |
| EP4616908A3 (en) | Oxysterols and methods of use thereof | |
| RU2012140185A (ru) | Ингибирование ангиогенеза | |
| EA201001687A1 (ru) | Производные имидазопиридина в качестве ингибиторов активиноподобной рецепторной киназы ( alk-4 или alk-5 ) | |
| EA201892207A1 (ru) | Индолкарбоксамидные соединения | |
| JP2016526540A5 (cg-RX-API-DMAC7.html) | ||
| JP2014521688A5 (cg-RX-API-DMAC7.html) | ||
| EA201692095A1 (ru) | Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака | |
| JP2017510661A5 (cg-RX-API-DMAC7.html) | ||
| RU2017112048A (ru) | Синергистические комбинации ауристана | |
| EA201692260A1 (ru) | Соединения 1,3,4-тиадиазола и их применение в лечении рака | |
| JP2018538248A5 (cg-RX-API-DMAC7.html) | ||
| AR088810A1 (es) | Moduladores del receptor mas acoplado a la proteina g utiles en el tratamiento de trastornos cardiovasculares y composiciones farmaceuticas que los contienen |